Burosumab

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Tumor Induced Osteomalacia (TIO)

Conditions

Tumor Induced Osteomalacia (TIO), Epidermal Nevus Syndrome (ENS)

Trial Timeline

Mar 24, 2015 → Jan 21, 2021

NCT ID

NCT02304367

About Burosumab

Burosumab is a phase 2 stage product being developed by Kyowa Kirin for Tumor Induced Osteomalacia (TIO). The current trial status is completed. This product is registered under clinical trial identifier NCT02304367. Target conditions include Tumor Induced Osteomalacia (TIO), Epidermal Nevus Syndrome (ENS).

What happened to similar drugs?

20 of 20 similar drugs in Tumor Induced Osteomalacia (TIO) were approved

Approved (20) Terminated (3) Active (0)

✅PexidartinibDaiichi SankyoApproved

✅KRN23Kyowa KirinApproved

✅DurvalumabAstraZenecaApproved

✅aprepitant + Dexamethasone and Ondansetron during CE-treatmentMerckApproved

✅Everolimus (RAD001)NovartisApproved

✅Chromogranin ANovartisApproved

✅Pasireotide + DiazoxideNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03775187	Pre-clinical	Active	—	—	X-linked Hypophosphatemia
NCT05181839	Pre-clinical	Completed	Nov 24, 2021	May 22, 2024	X-Linked Hypophosphatemia
NCT04695860	Phase 3	Completed	Jan 7, 2021	Mar 17, 2023	X-linked Hypophosphatemia
NCT04188964	Phase 1/2	Completed	Feb 26, 2020	Mar 6, 2024	X-linked Hypophosphatemia (XLH)
NCT03920072	Phase 3	Completed	Mar 7, 2019	Apr 7, 2022	X-linked Hypophosphatemia
NCT02750618	Phase 2	Completed	May 5, 2016	Sep 10, 2019	X-Linked Hypophosphatemia
NCT02537431	Phase 3	Completed	Dec 23, 2015	Dec 13, 2018	X-linked Hypophosphatemia
NCT02526160	Phase 3	Completed	Oct 22, 2015	Dec 6, 2018	X-linked Hypophosphatemia
NCT02304367	Phase 2	Completed	Mar 24, 2015	Jan 21, 2021	Tumor Induced Osteomalacia (TIO)
NCT02163577	Phase 2	Completed	Jul 2, 2014	Oct 30, 2018	X-linked Hypophosphatemia

Competing Products

20 competing products in Tumor Induced Osteomalacia (TIO)

See all competitors

Product	Company	Stage	Hype Score
ALG.APV-527	Alligator Bioscience AB	Phase 1/2	18
ATOR-1017	Alligator Bioscience AB	Phase 1	19
ATOR-1015	Alligator Bioscience AB	Phase 1	19
mRNA-4359	Moderna	Phase 2	0
mRNA-2752 + Durvalumab	AstraZeneca	Phase 1	29
mRNA-4106	Moderna	Phase 1	0
mRNA-4157 + Pembrolizumab + SoC Treatment	Merck	Phase 1	33
mRNA-2416	Moderna	Phase 2	0
E7050	Eisai	Phase 1	29
Fruquintinib	HUTCHMED	Phase 1	23
AFM24 + Atezolizumab 840 MG in 14 ML Injection	Affimed	Phase 1/2	14
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)	Syros Pharmaceuticals	Phase 1	11
BBP-398 + sotorasib	BridgeBio Pharma	Phase 1	18
BBP-398 (Formerly known as IACS-15509)	BridgeBio Pharma	Phase 1	18
Cixutumumab	Eli Lilly	Phase 1	29
SON-1010	Sonnet BioTherapeutics	Phase 1	27
SON-1010	Sonnet BioTherapeutics	Phase 1/2	18
[203Pb]VMT-α-NET + [212Pb]VMT-α-NET	Perspective Therapeutics	Phase 1/2	33
[203Pb]VMT-α-NET	Perspective Therapeutics	Phase 1	27
[212Pb] VMT-α-NET	Perspective Therapeutics	Phase 1	27